Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromones | 9 | 2023 | 54 | 1.360 |
Why?
|
| Drug Compounding | 13 | 2024 | 76 | 0.980 |
Why?
|
| Chromatography, High Pressure Liquid | 13 | 2024 | 421 | 0.870 |
Why?
|
| Drug Stability | 15 | 2024 | 116 | 0.810 |
Why?
|
| Suspensions | 13 | 2024 | 46 | 0.780 |
Why?
|
| Fenretinide | 2 | 2015 | 8 | 0.640 |
Why?
|
| Nanoparticles | 3 | 2015 | 318 | 0.550 |
Why?
|
| Administration, Oral | 14 | 2024 | 224 | 0.520 |
Why?
|
| Povidone | 1 | 2014 | 5 | 0.510 |
Why?
|
| Artemisinins | 1 | 2014 | 20 | 0.480 |
Why?
|
| Drug Carriers | 7 | 2015 | 125 | 0.470 |
Why?
|
| Antimalarials | 1 | 2014 | 55 | 0.460 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 132 | 0.450 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 803 | 0.370 |
Why?
|
| Drug Storage | 7 | 2023 | 27 | 0.330 |
Why?
|
| Solubility | 6 | 2015 | 118 | 0.320 |
Why?
|
| Polymers | 4 | 2015 | 121 | 0.270 |
Why?
|
| Particle Size | 8 | 2015 | 215 | 0.260 |
Why?
|
| Clonidine | 1 | 2024 | 52 | 0.240 |
Why?
|
| Azathioprine | 1 | 2023 | 5 | 0.230 |
Why?
|
| Calorimetry, Differential Scanning | 5 | 2015 | 30 | 0.230 |
Why?
|
| Excipients | 4 | 2023 | 22 | 0.230 |
Why?
|
| Pyrimethamine | 1 | 2023 | 10 | 0.220 |
Why?
|
| 2,4-Dinitrophenol | 1 | 2003 | 4 | 0.220 |
Why?
|
| Radiation-Protective Agents | 2 | 2016 | 14 | 0.220 |
Why?
|
| Amitriptyline | 1 | 2022 | 9 | 0.210 |
Why?
|
| Polyglycolic Acid | 5 | 2015 | 37 | 0.210 |
Why?
|
| Lactic Acid | 5 | 2015 | 95 | 0.200 |
Why?
|
| Biosensing Techniques | 1 | 2003 | 86 | 0.200 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2015 | 71 | 0.190 |
Why?
|
| Metronidazole | 1 | 2021 | 13 | 0.190 |
Why?
|
| Amifostine | 3 | 2008 | 9 | 0.190 |
Why?
|
| Polyglactin 910 | 3 | 2015 | 9 | 0.190 |
Why?
|
| Hydrocortisone | 1 | 2021 | 78 | 0.190 |
Why?
|
| Allopurinol | 1 | 2020 | 12 | 0.190 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2015 | 142 | 0.190 |
Why?
|
| Drug Delivery Systems | 4 | 2004 | 202 | 0.190 |
Why?
|
| Uric Acid | 1 | 2020 | 26 | 0.180 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2000 | 21 | 0.180 |
Why?
|
| Amlodipine | 1 | 2019 | 21 | 0.180 |
Why?
|
| Surface-Active Agents | 1 | 2000 | 41 | 0.170 |
Why?
|
| Serum Albumin, Bovine | 1 | 2000 | 51 | 0.170 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 5 | 0.170 |
Why?
|
| Naltrexone | 1 | 2019 | 38 | 0.170 |
Why?
|
| Chitosan | 2 | 2009 | 36 | 0.160 |
Why?
|
| Caco-2 Cells | 2 | 2015 | 52 | 0.160 |
Why?
|
| Permeability | 2 | 2015 | 67 | 0.160 |
Why?
|
| Sulfadiazine | 1 | 2017 | 4 | 0.150 |
Why?
|
| Trimethoprim | 1 | 2017 | 6 | 0.150 |
Why?
|
| Chromans | 1 | 2016 | 15 | 0.140 |
Why?
|
| Spironolactone | 1 | 2017 | 39 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 284 | 0.140 |
Why?
|
| Clindamycin | 1 | 2016 | 13 | 0.140 |
Why?
|
| Vitamin E | 1 | 2016 | 61 | 0.140 |
Why?
|
| Squalene | 1 | 2015 | 3 | 0.130 |
Why?
|
| Mebendazole | 1 | 2015 | 4 | 0.130 |
Why?
|
| Tubulin Modulators | 1 | 2015 | 18 | 0.130 |
Why?
|
| X-Ray Diffraction | 1 | 2014 | 57 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2015 | 127 | 0.120 |
Why?
|
| Calibration | 1 | 2014 | 56 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2014 | 59 | 0.120 |
Why?
|
| Humans | 12 | 2023 | 37093 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 160 | 0.110 |
Why?
|
| Insulin | 1 | 2015 | 236 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 352 | 0.110 |
Why?
|
| Pentamidine | 2 | 2004 | 9 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2017 | 364 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 935 | 0.090 |
Why?
|
| Viscosity | 3 | 2017 | 38 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 485 | 0.090 |
Why?
|
| Technology, Pharmaceutical | 4 | 2015 | 27 | 0.090 |
Why?
|
| Propranolol | 1 | 2009 | 18 | 0.080 |
Why?
|
| Child | 3 | 2021 | 3131 | 0.080 |
Why?
|
| Indomethacin | 1 | 2008 | 28 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 121 | 0.070 |
Why?
|
| Capsules | 4 | 2008 | 25 | 0.070 |
Why?
|
| Glycolates | 1 | 2004 | 6 | 0.060 |
Why?
|
| Lactose | 2 | 2016 | 14 | 0.060 |
Why?
|
| Polyvinyl Alcohol | 1 | 2002 | 5 | 0.050 |
Why?
|
| Nanostructures | 1 | 2004 | 134 | 0.050 |
Why?
|
| Antibodies | 1 | 2003 | 141 | 0.050 |
Why?
|
| Hydrogels | 1 | 2002 | 37 | 0.050 |
Why?
|
| Temperature | 2 | 2016 | 286 | 0.050 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2008 | 19 | 0.040 |
Why?
|
| Solvents | 2 | 2008 | 99 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 98 | 0.040 |
Why?
|
| Acute Radiation Syndrome | 1 | 2016 | 2 | 0.040 |
Why?
|
| Emulsions | 1 | 2016 | 33 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1039 | 0.040 |
Why?
|
| Molecular Weight | 2 | 2009 | 167 | 0.040 |
Why?
|
| Poloxamer | 1 | 2015 | 9 | 0.030 |
Why?
|
| Transition Temperature | 1 | 2015 | 8 | 0.030 |
Why?
|
| Intestinal Absorption | 1 | 2015 | 20 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 80 | 0.030 |
Why?
|
| Esters | 1 | 2015 | 28 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2015 | 98 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 84 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 122 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 204 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 260 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 708 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2015 | 353 | 0.030 |
Why?
|
| Mice | 2 | 2016 | 5913 | 0.020 |
Why?
|
| Sodium Bicarbonate | 1 | 2009 | 8 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 6741 | 0.020 |
Why?
|
| Citric Acid | 1 | 2009 | 9 | 0.020 |
Why?
|
| Tablets | 1 | 2009 | 9 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 5363 | 0.020 |
Why?
|
| Methylene Chloride | 1 | 2008 | 6 | 0.020 |
Why?
|
| Nanocapsules | 1 | 2008 | 17 | 0.020 |
Why?
|
| Cations | 1 | 2008 | 45 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2008 | 47 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 88 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2008 | 60 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 15081 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2004 | 207 | 0.010 |
Why?
|
| Male | 2 | 2016 | 20025 | 0.010 |
Why?
|
| Microspheres | 1 | 2001 | 49 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 2001 | 80 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 1742 | 0.010 |
Why?
|